Navigation Links
The Leukemia & Lymphoma Society Issues Statement Regarding the Status of Iclusig (Ponatinib)
Date:11/1/2013

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML).  As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug.  Those patients who are responding well to ponatinib, and who are not eligible for therapeutic alternatives, may be able to obtain ponatinib on a compassionate use basis, but need to speak with their oncologists immediately.

We are here to advise patients how the recent news applies to them and what discussions to have with their physicians.  Patients can contact LLS's Information Resource Center at 1-800-955-4572, Monday through Friday from 9 a.m. to 6 p.m. ET.

LLS recognizes the need and urgency for new treatments for CML.  In 2013, we committed $1.7 million to CML research ranging from basic science to clinical research on how best to use new therapies.

"The Leukemia & Lymphoma Society exists to find cures and ensure access to treatments for blood cancer patients," said Mark Velleca, MD, PhD, chief policy and advocacy officer for LLS.  "As such, we felt it was important to comment on this important access issue.  Working with CML physicians and other advocacy groups, we have requested that FDA facilitate continued access to ponatinib for certain patients – such as those in blast crisis – for whom interruption of therapy could be extremely detrimental."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, a
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
4. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
5. Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine
6. Celebrating 25 Years and Counting: Leukemia and Lymphoma Societys "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients
7. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
8. The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute to Bring Clinical Trials to Local Communities
9. The Leukemia & Lymphoma Society Applauds FDAs Approval of Lenalidomide for Patients with Relapsed or Refractory Mantle Cell Lymphoma
10. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
11. Leading Leukemia Experts: High Leukemia Treatment Costs May Be Harming Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... bloggers and influencers across North America ... that melanoma prevention begins with parents-encouraging everyone to create a ... Duff , and parenting author Alyson Schafer are ... Monday to share this poignant video message: Click ... Cornfield Melanoma Fund (DCMF)-producers of the viral video ...
(Date:5/6/2015)... , May 06, 2015 Research and ... the addition of the "Cannulas Market by ... Injector, Infusion, Venous, Microcannula), Material (Plastic, Metal) & ... Forecast to 2020" report to their offering. ... to grow at a CAGR of 5.6% from ...
(Date:5/6/2015)... Maine , May 6, 2015  Membership in ... according to a Healthcare Business Strategy report released ... also known as Medigap or Med Supp plans, ... 31, 2014, a 5.2% increase from 2013. Between ... increased by 551,135 covered lives.  Though UnitedHealth was ...
Breaking Medicine Technology:Celebrities Tweet Their Support of Melanoma Awareness Month and #newfamilyrule 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 2Global Cannulas Market 2015 - Forecasts to 2020 with Medtronic, Edward Lifesciences, Terumo, Sorin & Maquet Holding B.V. & Co. Dominating 3Continued Growth in Med Supp Market for 2014 according to Mark Farrah Associates 2
... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announced ... Highly Selective MEK1/2 Inhibitor is Beneficial in Dextran ... was presented at the,American College of Gastroenterology (ACG) ... provided data from a preclinical study of,RDEA119, the ...
... ,Sosei Group Corporation ("Sosei"; TSE Mothers Index: ... announce results of two Phase II studies,evaluating ... presented at the,annual congress of the European ... data show that NVA237 (glycopyrronium bromide), a ...
Cached Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5
(Date:5/6/2015)... MA (PRWEB) May 06, 2015 ... for healthcare professionals and students, announced today that in ... 94% confirmed that use of the clinical decision support ... by the end of 2014, UpToDate users in more ... clinical topics per month, on average. In Germany alone, ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... In March, Dr. Rami K. Batniji ... Masterclass. As Europe’s most exclusive rhinoplasty conference, the attendees ... Dr. Batniji was hand chosen to speak by the President ... Dr. Pietro Palma. , The Milano Masterclass is ... hosts a diverse, multi-national faculty; each considered a rhinoplasty expert ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and ... week as having one the best Extra Virgin Olive Oils ... Peloponnese region of Greece and known as Laconiko , ... of Medium Olive Oil, which is defined by the competition ... over 700 producer applicants from 25 different countries applying, Laconiko ...
(Date:5/6/2015)... The Alliance for Regenerative Medicine ... and advanced therapies community, today announced the release ... in-depth look at sector trends and metrics from ... report is available online here and ... available here . , Using information provided ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... labels to help cut heart disease, according to researchers from ... their arguments in this week's British Medical Journal, say that ... number one killer, estimated to be responsible for almost 50 ... cardiovascular disease is reported to cost the EU economy an ...
... because a staff nurse has refused to send an ambulance to ... had an agonizing pain in her lower abdomen. Hence she called ... could not have an ambulance and had to wait for another ... the GP arrived he just gave her some painkillers. ...
... 35-year-old woman in Madhya Pradesh survived carrying a dead foetus ... Friday at the government hospital at Khargone, 348 km from ... removed from her womb. ,Renubai conceived two years ... the seventh month of her pregnancy, her family members thought ...
... it has received the tentative new drug approval ... anti-HIV treatment. // ,The fixed drug ... Abacavir 300mg Tablets, the company informed the Bombay ... is cost-effective and reduces the threat of resistance ...
... of a bird flu vaccine against the deadly H5N1 variety ... unvaccinated monkeys, by researchers at two universities.// ,According ... University, the results are expected to be known within about ... shed light on numerous aspects of the strain's infection mechanism ...
... Act, celebrating its third anniversary, has reduced secondhand smoke ... a study conducted by RTI International. ,According to ... of Health’s Tobacco Control Program, exposure to secondhand smoke ... in the year following the implementation of the law. ...
Cached Medicine News:Health News:Scientists Push for Labeling of all Fats to Avoid Heart Disease 2Health News:New York’s Secondhand Smoke Exposure Continues to Declin 2
... combining the corrosion resistance of stainless ... of copper, SANYO offers an electro-polished ... and maintenance-free. The sterile environment promotes ... results and the safety of laboratory ...
ArcticTemp Upright Freezer -20C. Quick, even freezing. Heavy duty compressor. Deep door racks. Front gated bottom shelf. Interior light. Locks One year warranty on unit and 5 year warranty on compres...
Undercounter Freezer -25C. White. Front opening freezer. 4 cubic ft capacity. Reversible door. Three slide-out drawers. Extra thick CFC insulation. Front lock. Front indicator lights. Attractive tabl...
... highly accurate portable, waterproof system for pH, mV ... pH results can be obtained when used with ... • This GLP/GMP compliant system includes an RS-232 ... computer. Up to 100 data sets can be ...
Medicine Products: